Literature DB >> 4018873

Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.

G M Bahr, D S Tello, L A Chedid.   

Abstract

Priming of mice with complexes of antigen coupled to muramyl dipeptide and monoclonal anti-muramyl dipeptide antibodies enhanced the adjuvant activity of muramyl dipeptide on the humoral response to the antigen. The enhancement did not occur with free (uncoupled) muramyl dipeptide and required the presence of an adjuvant-active hapten within the complex as well as the Fc fragment of the monoclonal antibody. This system proved highly effective in eliciting antibodies to synthetic weak immunogens whereas muramyl dipeptide, on its own, exerts very little or no adjuvant activity. The effect was not due to a general polyclonal activation and was restricted to the antigen coupled to the synthetic adjuvant. Possible pathways involved in this phenomenon are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018873      PMCID: PMC262016          DOI: 10.1128/iai.49.2.312-319.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  A modified colorimetric method for the estimation of N-acetylamino sugars.

Authors:  J L REISSIG; J L STORMINGER; L F LELOIR
Journal:  J Biol Chem       Date:  1955-12       Impact factor: 5.157

2.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

3.  Specific antibody-mediated effect on the immune response. Suppression and augmentation of the primary immune response in mice by different classes of antibodies.

Authors:  R A Murgita; S I Vas
Journal:  Immunology       Date:  1972-03       Impact factor: 7.397

4.  Studies on the control of antibody synthesis. Effect of antibody affinity upon its ability to suppress antibody formation.

Authors:  J G Walker; G W Siskind
Journal:  Immunology       Date:  1968-01       Impact factor: 7.397

5.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

6.  The mechanism of a hapten-specific helper effect in mice.

Authors:  C A Janeway
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

7.  Suppression and augmentation of the primary in vitro immune response by different classes of antibodies.

Authors:  J Gordon; R A Murgita
Journal:  Cell Immunol       Date:  1975-02       Impact factor: 4.868

8.  Modulation of the immune response by passive antibodies. I. Anti-hapten antibodies enhanced delayed hypersensitivity to the carrier and depressed antibody synthesis to the hapten.

Authors:  P J Neveu; A G Borduas
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

9.  Inhibition of the immune response by 7S antibody mechanism and site of action.

Authors:  S Abrahams; R A Phillips; R G Miller
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

10.  Immunological adjuvants and the mechanism of cell cooperation.

Authors:  J Maillard; B R Bloom
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  1 in total

1.  Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation.

Authors:  M Ruhl; M Himmelspach; G M Bahr; F Hammerschmid; H Jaksche; B Wolff; H Aschauer; G K Farrington; H Probst; D Bevec
Journal:  J Cell Biol       Date:  1993-12       Impact factor: 10.539

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.